Korro Bio, Inc. (KRRO) Financial Analysis & Valuation | Quarter Chart
Korro Bio, Inc. (KRRO)
KRROPrice: $11.5
Fair Value: 🔒
🔒score
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medici... more
Description
Shares
| Market Cap | $108.30M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Ram Aiyar |
| IPO Date | 2019-10-03 | CAGR | — |
| Employees | 112 | Website | www.korrobio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KRRO chart loading...
Fundamentals
Technicals
| Enterprise Value | $180.43M | P/E Ratio | -1.19 |
| Forward P/E | -1.83 | PEG Ratio | — |
| P/S Ratio | 11083035304773636 | P/B Ratio | 602891679010388.12 |
| P/CF Ratio | -1027867701345181.25 | P/FCF Ratio | -961802298634619.5 |
| EPS | $-9.65 | EPS Growth 1Y | -21.71% |
| EPS Growth 3Y | -90.48% | EPS Growth 5Y | -72.88% |
| Revenue Growth 1Y | inf% | Gross Margin | 0.67% |
| Operating Margin | -15.69% | Profit Margin | -14.54% |
| ROE | -0.62% | ROA | -0.51% |
| ROCE | -0.6% | Current Ratio | 5.98 |
| Quick Ratio | 5.98 | Cash Ratio | 1.96 |
| Debt/Equity | 0.39 | Interest Coverage | — |
| Altman Z Score | 0.34 | Piotroski Score | 3 |